Curis (NASDAQ:CRIS) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?

Curis, Inc. (NASDAQ:CRIS) passed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $0.88 and traded as high as $1.60. Curis shares last traded at $1.1140, with a volume of 162,381,274 shares changing hands.

Curis News Roundup

Here are the key news stories impacting Curis this week:

• Positive Sentiment: Investor interest in the reverse-split vote and anticipated clinical data appears to be driving buying activity. The reverse split itself does not improve the company’s underlying fundamentals, and the clinical data has not yet been reported.
• Neutral Sentiment: Repeated LULD trading pauses indicate unusually volatile trading, but do not represent a separate company announcement or fundamental catalyst.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on CRIS shares. Wall Street Zen raised Curis from a “strong sell” rating to a “hold” rating in a report on Saturday, August 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a report on Thursday, October 15th. HC Wainwright reaffirmed a “buy” rating on shares of Curis in a research note on Monday, August 17th. Finally, Zacks Research raised Curis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, September 9th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $43.00.

Curis Price Performance

The firm’s 50-day simple moving average is $0.88 and its 200 day simple moving average is $8.84. The firm has a market capitalization of $2.33 million, a price-to-earnings ratio of -0.08 and a beta of 3.28.

Curis (NASDAQ:CRIS) last issued its earnings results on Friday, August 14th. The biotechnology company reported ($4.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($6.95) by $2.93. As a group, research analysts predict that Curis, Inc. will post -15.65 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Focused Wealth Management Inc bought a new stake in shares of Curis during the 2nd quarter valued at approximately $26,000. BlackRock Inc. acquired a new position in Curis during the 2nd quarter worth approximately $28,000. Flputnam Investment Management Co. acquired a new position in Curis during the 2nd quarter worth approximately $128,000. Renaissance Technologies LLC increased its position in Curis by 52.2% during the 1st quarter. Renaissance Technologies LLC now owns 366,740 shares of the biotechnology company’s stock worth $201,000 after purchasing an additional 125,823 shares in the last quarter. Finally, Cable Car Capital LP bought a new position in Curis in the 2nd quarter valued at approximately $696,000. Institutional investors and hedge funds own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc is a clinical-stage biotechnology company focused on developing innovative therapeutics for the treatment of cancer. The company’s research and development activities center on targeted therapies designed to address biological pathways involved in tumor growth and immune regulation.

Curis’ lead investigational product is emavusertib, an oral inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). The company has evaluated emavusertib in clinical studies for hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes and certain forms of non-Hodgkin lymphoma.